v3.25.1
Trade and other liabilities and other non-current liabilities - Narrative (Details)
12 Months Ended
Dec. 31, 2024
EUR (€)
Y
Dec. 31, 2023
Dec. 31, 2022
Jun. 21, 2022
EUR (€)
Discount rate | Contingent consideration liabilities [member]        
Business combinations during the period        
Percentage of reasonably possible increase in unobservable input, liabilities 1.00%      
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities € (600,000)      
Time Frame [member] | Contingent consideration liabilities [member]        
Business combinations during the period        
Key assumptions in valuation of contingent consideration liability. | Y 1      
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities € (2,500,000)      
Cell Point Acquisition        
Business combinations during the period        
Fair value of contingent consideration       € 20,211,000
Contingent consideration on certain development milestone       20,000,000
Contingent consideration on regulatory milestone       30,000,000
Contingent consideration on sales based milestone       50,000,000
Cell Point Acquisition | Discount rate        
Business combinations during the period        
Key assumptions in valuation of contingent consideration liability. 13.75 13.72 12.5  
Cell Point Acquisition | Probabilities Of Success [member]        
Business combinations during the period        
Percentage of reasonably possible increase in unobservable input, liabilities 5.00%      
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities € 2,900,000      
Cell Point Acquisition | Maximum        
Business combinations during the period        
Additional contingent consideration       € 100,000,000